Journal
GENES
Volume 13, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/genes13030528
Keywords
Phelan-McDermid syndrome; phenotypic variability; SHANK3; 22q13 deletion; haploinsufficiency; PNPLA3; epigenetics; BRD1; pharmacogenomics
Categories
Funding
- Intramural Research Program of the National Institute of Mental Health, National Institutes of Health [ZICMH002961, ZIAMH002886]
Ask authors/readers for more resources
Phelan-McDermid syndrome is a multi-systemic disorder characterized by genetic and phenotypic variability. It presents with a wide range of clinical features including intellectual disability, developmental delay, and minor dysmorphic facial features. The syndrome can be caused by genetic abnormalities affecting the SHANK3 gene or chromosomal rearrangements in the 22q13 region. Environmental factors and variations in specific genes can also contribute to the variability in clinical presentation.
Phelan-McDermid syndrome (PMS) is a multi-systemic disorder characterized by both genetic and phenotypic variability. Genetic abnormalities causing PMS span from pathogenic variants of the SHANK3 gene to chromosomal rearrangements affecting the 22q13 region and leading to the loss of up to over nine megabases. The clinical presentation of individuals with PMS includes intellectual disability, neonatal hypotonia, delayed or absent speech, developmental delay, and minor dysmorphic facial features. Several other features may present with differences in age of onset and/or severity: seizures, autism, regression, sleep disorders, gastrointestinal problems, renal disorders, dysplastic toenails, and disrupted thermoregulation. Among the causes of this phenotypic variability, the size of the 22q13 deletion has effects that may be influenced by environmental factors interacting with haploinsufficiency or hemizygous variants of certain genes. Another mechanism linking environmental factors and phenotypic variability in PMS involves the loss of one copy of genes like BRD1 or CYP2D6, located at 22q13 and involved in the regulation of genomic methylation or pharmacokinetics, which are also influenced by external agents, such as diet and drugs. Overall, several non-mutually exclusive genetic and epigenetic mechanisms interact with environmental factors and may contribute to the clinical variability observed in individuals with PMS. Characterization of such factors will help to better manage this disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available